Benjamin Huang

List of Publications by Year
in descending order

25 papers	418 citations	1163117 8 h-index	1058476 14 g-index
25 all docs	25 docs citations	25 times ranked	886 citing authors

#	Article	IF	Citations
1	KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell, 2017, 168, 817-829.e15.	28.9	148
2	Mutant Ikzf1, Kras ^{G12D} , and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5106-5111.	7.1	60
3	ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nature Chemical Biology, 2021, 17, 856-864.	8.0	49
4	Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 194-207.	5.0	38
5	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. Journal of Clinical Investigation, 2020, 130, 863-876.	8.2	36
6	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2025-2037.	7.2	27
7	Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood, 2020, 135, 1772-1782.	1.4	18
8	Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Advances, 2021, 5, 1437-1441.	5.2	15
9	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood, 2016, 128, 753-753.	1.4	7
10	Inhibition of the Sec61 translocon overcomes cytokineâ€induced glucocorticoid resistance in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2022, , .	2.5	6
11	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. PLoS Genetics, 2019, 15, e1008168.	3.5	5
12	CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Advances, 2021, 5, 4963-4968.	5.2	4
13	Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Molecular Cancer Therapeutics, 2020, 19, 2382-2395.	4.1	3
14	Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate. Blood, 2021, 138, 209-209.	1.4	1
15	Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. Blood, 2020, 136, 20-21.	1.4	1
16	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. Journal of Clinical Oncology, 2021, 39, 10002-10002.	1.6	0
17	Expressing N-RasG12D from the Endogenous Promoter Induces Myeloproliferative Disease (MPD) and Cooperates with Retroviral Insertional Mutagenesis (RIM) To Generate Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1616-1616.	1.4	0
18	Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders. Blood, 2014, 124, 1155-1155.	1.4	0

#	Article	IF	Citations
19	Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling. Blood, 2016, 128, 1654-1654.	1.4	0
20	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 913-913.	1.4	0
21	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2019, 37, 10033-10033.	1.6	0
22	EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (FUS-ERG). Blood, 2021, 138, 374-374.	1.4	0
23	Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia. Blood, 2020, 136, 31-32.	1.4	0
24	Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML. Blood, 2020, 136, 5-6.	1.4	0
25	Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia. Blood, 2020, 136, 28-29.	1.4	0